Nivolumab receptor occupancy on effector regulatory T cells predicts clinical benefit.
Hosonuma M, Hirasawa Y, Kuramasu A, Murayama M, Narikawa Y, Toyoda H, Baba Y, Isobe J, Funayama E, Tajima K, Shida M, Hamada K, Tsurui T, Ariizumi H, Ishiguro T, Suzuki R, Ohkuma R, Kubota Y, Horiike A, Sambe T, Tsuji M, Wada S, Kiuchi Y, Kobayashi S, Tsunoda T, Yoshimura K.
Hosonuma M, et al. Among authors: horiike a.
Cancer Sci. 2024 Mar;115(3):752-762. doi: 10.1111/cas.16061. Epub 2024 Jan 22.
Cancer Sci. 2024.
PMID: 38254257
Free PMC article.